REGENXBIO Inc. (RGNX)

REGENXBIO Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	90.24	112.72	470.35	154.57	35.23
Revenue Growth (YoY)	-19.94%	-76.03%	204.30%	338.70%	-83.88%
Cost of Revenue	37.21	54.55	51.83	35.71	8.24
Gross Profit	53.03	58.18	418.51	118.85	26.99
Selling, General & Admin	88.49	85.28	79.33	63.82	51.82
Research & Development	232.27	242.45	181.44	166.29	124.19
Other Operating Expenses	0.4	-6.68	-2.24	7.98	-0.01
Operating Expenses	321.16	321.06	258.53	238.09	175.99
Operating Income	-268.13	-262.88	159.98	-119.23	-149
Interest Expense / Income	6.86	23.25	26.28	0.77	0
Other Expense / Income	-11.34	-5.73	-7.54	-13.99	-51.51
Pretax Income	-263.65	-280.41	141.25	-106.01	-97.49
Income Tax	-0.15	-0.08	13.41	5.24	-2.76
Net Income	-263.49	-280.32	127.84	-111.25	-94.73
Shares Outstanding (Basic)	44	43	42	37	37
Shares Outstanding (Diluted)	44	43	44	37	37
Shares Change	1.35%	-1.73%	17.79%	1.61%	0.11%
EPS (Basic)	-6.02	-6.50	3.01	-2.98	-2.58
EPS (Diluted)	-6.02	-6.50	2.91	-2.98	-2.58
Free Cash Flow	-228.37	-238.21	134.7	-80.93	-119.43
Free Cash Flow Per Share	-5.22	-5.52	3.17	-2.17	-3.25
Gross Margin	58.76%	51.61%	88.98%	76.89%	76.61%
Operating Margin	-297.12%	-233.20%	34.01%	-77.14%	-422.89%
Profit Margin	-291.99%	-248.68%	27.18%	-71.98%	-268.88%
Free Cash Flow Margin	-253.06%	-211.32%	28.64%	-52.36%	-338.96%
Effective Tax Rate	-	-	9.49%	-	-
EBITDA	-239.46	-244.24	177.09	-96.83	-90.34
EBITDA Margin	-265.36%	-216.67%	37.65%	-62.65%	-256.40%
Depreciation & Amortization	17.32	12.91	9.56	8.41	7.15
EBIT	-256.78	-257.15	167.52	-105.24	-97.49
EBIT Margin	-284.55%	-228.12%	35.62%	-68.09%	-276.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).